Newron Pharmaceuticals S.p.A. (NWRN.SW)

CHF 7.98

(-2.68%)

Market Cap (In CHF)

159.27 Million

Revenue (In CHF)

9.05 Million

Net Income (In CHF)

-16.22 Million

Avg. Volume

86.76 Thousand

Currency
CHF
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
4.25-11.2
PE
-8.14
EPS
-0.98
Beta Value
0.65
ISIN
IT0004147952
CUSIP
-
CIK
-
Shares
19958900.0
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Biotechnology
CEO
Mr. Stefan Weber
Employee Count
-
Website
https://www.newron.com
Ipo Date
2006-12-12
Details
Newron Pharmaceuticals S.p.A., a clinical stage biopharmaceutical company, focuses on the research and development of therapies for the treatment of central and peripheral nervous system, and pain in Italy and the United States. The company offers Xadago (safinamide) for the treatment of Parkinson's disease, as well as develops Xadago for the treatment of levodopa induced dyskinesia. It also develops Evenamide for Schizophrenia and treatment resistant schizophrenia; and Ralfinamide for orphan indication in neuropathic pain. Newron Pharmaceuticals S.p.A. was founded in 1999 and is headquartered in Bresso, Italy.